34,017 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Purchased by Qsemble Capital Management LP

Qsemble Capital Management LP acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 34,017 shares of the company’s stock, valued at approximately $224,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at about $25,000. Farther Finance Advisors LLC increased its position in Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after acquiring an additional 6,036 shares in the last quarter. KBC Group NV increased its position in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank increased its position in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 8.3 %

Shares of NASDAQ RXRX opened at $6.38 on Thursday. The stock has a market cap of $1.83 billion, a P/E ratio of -3.85 and a beta of 0.81. The firm has a 50 day moving average price of $6.59 and a 200 day moving average price of $7.45. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.43) EPS. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Jefferies Financial Group lowered their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $9.25.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. The trade was a 2.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 165,682 shares of company stock worth $1,088,111. 15.75% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.